Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:52:36.006Z.
Calculation as of: 2026-10-06T17:52:36.006Z.
Quote observation: 2026-10-06T17:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$445.64M
EV/EBIT Ratio
N/A
TTM Avg
84.81x
3Y Avg
33.20x
5Y Avg
21.83x
Market Cap
$444.69M
EV/EBIT Ratio
N/A
TTM Avg
0.21x
3Y Avg
0.21x
5Y Avg
0.21x
Market Cap
$441.97M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $446.29M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $445.64M | N/A | 84.81x | 33.20x | 21.83x |
| Ovid Therapeutics Inc. (OVID)vs › | $444.69M | N/A | 0.21x | 0.21x | 0.21x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $441.97M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $457.04M | 36.90x | 22.84x | 18.67x | 19.86x |
| Assembly Biosciences, Inc. (ASMB)vs › | $433.90M | N/A | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $432.39M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $430.34M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $428.59M | N/A | 64.08x | 60.43x | 132.37x |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
